Literature DB >> 30138683

Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia.

Paolo Capogrosso1, Umberto Capitanio2, Emily A Vertosick3, Eugenio Ventimiglia2, Francesco Chierigo2, Davide Oreggia2, Donatella Moretti4, Alberto Briganti2, Andrew J Vickers3, Francesco Montorsi2, Andrea Salonia2.   

Abstract

OBJECTIVE: To assess changes in the rate of incidental prostate cancer (PCa) after benign prostatic hyperplasia (BPH) surgery over the last decade.
MATERIALS AND METHODS: We identified 1177 patients surgically treated for BPH (open prostatectomy, transurethral resection or holmium laser enucleation [HoLEP] of the prostate) in 2007-2016 at a single European academic center. Local polynomial regression was used to explore changes in the rate of incidental PCa detected after BPH surgery and of preoperative biopsy performed over time. Logistic regression analyses tested the association of incidental PCa diagnosis with year of surgery and preoperative biopsy.
RESULTS: Incidental PCa was found in 6.4% (74) of cases, 67 (91%) with Grade group 1 disease. We observed an increased incidence of PCa diagnosis after BPH surgery over time (odds ratio [OR]: 1.12; 95%confidence interval [CI]: 1.02-1.24, P = .02) along with a concomitant decrease in the rate of preoperative prostate biopsies (OR: 0.83; 95%CI: 0.79-0.88, P < .0001). Patients undergoing a preoperative biopsy showed a lower risk of being diagnosed with PCa after surgery (OR: 0.29; 95% CI: 0.12, 0.72 P = .007). Patients treated with HoLEP had a higher chance of incidental PCa detection (OR: 2.28; 95%CI: 1.30-4.00; P = .004), although this may be related to the significantly higher number of HoLEP performed over the last years.
CONCLUSION: The increased rate of low-risk PCa detected after BPH surgery in the last decade reflects the clinical practice changes in PCa screening and diagnosis leading to a reduced number of unnecessary biopsies and indolent cancer diagnosis.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30138683      PMCID: PMC6724539          DOI: 10.1016/j.urology.2018.07.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.

Authors:  Mattia Luca Piccinelli; Stefano Luzzago; Giulia Marvaso; Ekaterina Laukhtina; Noriyoshi Miura; Victor M Schuettfort; Keiichiro Mori; Abdulmajeed Aydh; Matteo Ferro; Francesco A Mistretta; Nicola Fusco; Giuseppe Petralia; Barbara A Jereczek-Fossa; Shahrokh F Shariat; Pierre I Karakiewicz; Ottavio de Cobelli; Gennaro Musi
Journal:  World J Urol       Date:  2021-10-23       Impact factor: 4.226

2.  Incidence and associated factors for incidental prostate cancer among patients who underwent surgery for benign prostatic hyperplasia: first report from Somalia.

Authors:  Abdikarim Hussein Mohamed; Ismail Mohamud Abdullahi; Feysal Farah Warsame; Hussein Ali Mohamud
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-29       Impact factor: 4.322

3.  Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression.

Authors:  Clément Klein; Thibault Marquette; Grégoire Capon; Mokrane Yacoub; Eric Alezra; Jean-Christophe Bernhard; Franck Bladou; Grégoire Robert
Journal:  Int J Clin Oncol       Date:  2022-03-25       Impact factor: 3.402

4.  Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study.

Authors:  Alisa Salmivalli; Otto Ettala; Peter J Boström; Ville Kytö
Journal:  World J Urol       Date:  2022-04-16       Impact factor: 3.661

5.  Age-related schwannomatosis with potential exosome-mediated contribution to prostate hyperplasia: a case report and mini-review.

Authors:  Bérengère Chignon-Sicard; Véronique Hofman; Daniel Chevallier; Jean-Michel Cucchi; Marius Ilié; Bérengère Dadone-Montaudié; Florence Paul; Xavier Carpentier; Hervé Quintens; Coraline Bence-Gauchiez; Didier Caselles; Jacqueline Rossant; Matthieu Durand; Roger Bertolotti
Journal:  Ther Adv Urol       Date:  2019-09-26

6.  Multiparametric MRI may Help to Identify Patients With Prostate Cancer in a Contemporary Cohort of Patients With Clinical Bladder Outlet Obstruction Scheduled for Holmium Laser Enucleation of the Prostate (HoLEP).

Authors:  Mike Wenzel; Maria N Welte; Lina Grossmann; Felix Preisser; Lena H Theissen; Clara Humke; Marina Deuker; Simon Bernatz; Philipp Gild; Sascha Ahyai; Pierre I Karakiewicz; Boris Bodelle; Luis A Kluth; Felix K H Chun; Philipp Mandel; Andreas Becker
Journal:  Front Surg       Date:  2021-02-25

7.  Incidental Prostate Cancer from Prostate with Benign Biopsies: A Predictive and Survival Analysis from Cohort Study.

Authors:  Che Hsueh Yang; Yi Sheng Lin; Wei Chun Weng; Chao Yu Hsu; Min Che Tung; Yen Chuan Ou
Journal:  Int J Gen Med       Date:  2022-03-10

8.  Prevalence and risk factors for incidental prostate cancer in patients after transurethral resection of the prostate with negative results on prostate biopsy: A retrospective study.

Authors:  Zhenlang Guo; Junwei He; Jun Pan; Lijuan Huang; Jiadong Cao; Zunguang Bai; Shusheng Wang; Songtao Xiang; Chiming Gu; Zhaohui Wang
Journal:  Investig Clin Urol       Date:  2022-03

9.  Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate.

Authors:  Hahn-Ey Lee; ByungWon Kim; Hyun Sik Yoon; Jungyo Suh; Seung-June Oh
Journal:  Int Neurourol J       Date:  2022-09-30       Impact factor: 3.038

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.